Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.38 EUR | +0.85% |
|
+3.72% | -5.83% |
06-25 | US CDC alerts healthcare providers of increase in dengue cases | RE |
06-25 | Takeda's Cancer Drug Gets European Commission Approval | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.96 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.83% | 41.02B | - | ||
+55.19% | 815B | C+ | ||
+45.45% | 654B | B | ||
-6.09% | 354B | C+ | ||
+21.92% | 337B | B- | ||
+10.18% | 302B | C+ | ||
+18.26% | 247B | B+ | ||
+2.41% | 229B | A+ | ||
+13.31% | 219B | B- | ||
+10.86% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
- Ratings Takeda Pharmaceutical Company Limited